CGM has advanced diabetes management, with demonstrated improvements in glycemic management, reduction of hypoglycemia-related resource utilization, and enhanced member engagement and self-management. While this technology was initially prescribed predominantly for those living with type 1 diabetes (T1D), the mounting body of evidence and expert recommendations have led to more widespread use in insulin-treated T2D, necessitating the implementation of evidence-based benefit design policies by health plans. During this working group meeting, leading payer and managed care decision makers reviewed recent findings and shared their insights on best practices for CGM coverage and reimbursement, including alignment with clinical practice guidelines, availability under the pharmacy benefit, and automated adjudication at the point of sale.
Jim Kenney, RPh, MBA (Moderator) Founder and President JTKenney, LLC
Sheri Dolan, BSPharm Clinical Pharmacist, Healthcare and Family Services Bureau of Professional and Ancillary Services University of Illinois at Chicago
Thomas Grace, MD Medical Director Blanchard Valley Diabetes Center
Estay Greene, PharmD, MBA Vice President of Pharmacy Zing Health
Eric Long, PharmD, MBA Disease Management Pharmacist Beacon Health System
Scott McClelland, PharmD Vice President, Commercial and Specialty Pharmacy Programs Florida Blue
Josh Moore, PharmD Director of Pharmacy MO HealthNet Division Missouri Department of Social Services
Diane E. Morgan, PharmD Director, Specialty Pharmacy Government Programs Pharmacy UnitedHealthcare
Heather Mullins, PMP Senior Clinical Program Manager UnitedHealthcare
Susan Wescott, RPh, MBA Executive Lead, Clinical Services, Alluma, LLC Senior Director of Pharmacy, Managed Care, Mayo Clinic
Source: AMCP Science and Innovation Theater Webinar – February 16, 2022
The Dexcom CGM system is unique with the ability to connect with multiple digital health solutions. Combining CGM with digital health apps allows users to quickly see all their data in one place. Access to real-time data can empower people with diabetes and foster patient engagement with in-the-moment diabetes feedback and the opportunity for coaching.
The recently updated American Diabetes Association (ADA) Standards of Care (SOC) 20221 revised the technology recommendations focusing on use of continuous glucose monitoring (CGM). In addition, the ADA added digital health to the recommendations noting the opportunity for digital coaching as a tool for education. Join this webinar for a deep dive into the updated CGM technology SOC and learn about the current evidence that influenced recent changes. Diabetes technology is evolving rapidly, stay up to date with CGM to enhance your knowledge.
1. American Diabetes Association. Diabetes Care. 2022;45(Suppl1):S97-S112
Presented by: Daniel DeSalvo, MD Assistant Professor of Pediatrics in the Section of Diabetes and Endocrinology Baylor College of Medicine/Texas Children’s Hospital Houston TX
In diverse and underserved populations research shows there are racial and ethnic disparities in diabetes outcomes. Disparities in diabetes technology use has the greatest influence on glycemic disparities between Black, Hispanic and Non-Hispanic White individuals. A study recently published in Diabetes Care found that lower socio-economic status was associated with lower rates of diabetes technology use and higher levels of A1C. Importantly, this gap in technology has widened over time. Data published from the T1D exchange, shows that across all age groups, individuals that use continuous glucose monitoring (CGM) have lower A1C levels compared to those who don’t use CGM.
This webinar will highlight the improvements in glycemic and psychosocial outcomes, along with best practices from recent research findings that support the use of CGM in diverse populations.
Source: AMCP Science and Innovation Theater Webinar – November 17, 2020
Key Takeaway: Advances in the Dexcom G6 technology are an important CGM differentiator that allows for improved safety, glycemic management and telehealth opportunities for persons 2 years and older through the use of real-time CGM data with features such as a predictive Urgent Low Soon alert, customizable high/low glycemic threshold alerts, remote monitoring and the CLARITY diabetes management application.
Key Takeaway: This webinar presented the first estimation of reduction in complications and costs associated with improving time-in-range per research found in the Advancing Glycemic Management in People with Diabetes report. The slides presented are available to help you learn about the Time-in-Range movement and gain an understanding about what’s to come in the realm of diabetes care management.
Intended Audience: Case Managers – During the CCMC New World Symposium that took place from February 28, 2019, to March 2, 2019, Nicholas B. Argento, MD, FACE, Diabetes Technology Director of Maryland Endocrine in Columbia, Maryland, presented a satellite breakfast symposium on continuous glucose monitoring (CGM) that was sponsored by Dexcom.
Source:AMCP Science and Innovation Theater Webinar
Description: Dexcom G6® is the first CGM to receive the integrated CGM classification by the FDA. Dexcom G6® is approved for use as a standalone CGM and for integration with bluetooth connected insulin pens and automated insulin delivery systems. This presentation will highlight Dexcom’s technology, connected ecosystem, Google/Verily partnership, and future developments including EHR integration, population-level insights, and decision support algorithms.
1-0 of 0 results
Sign Up To Stay Current On The Latest Coverage
Updates, Recent News, And Resources